OMCL
Omnicell, Inc.
Healthcare · Health Information Services · NMS
$43.00
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$2.0B
Total market value of the company
98.00
Expensive — high growth expected
19.64
Based on estimated future earnings — lower means cheaper
Rev Growth
+14.9%
Year-over-year revenue change
Profit Margin
1.7%
How much profit the company keeps from each dollar of revenue
1.6%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$60.00
+40% from current price — median analyst estimate
Recommendation
NONE
Consensus view from 7 analysts covering this stock
About Omnicell, Inc.

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

https://www.omnicell.com

Country: United States Employees: 3,525 Industry: Health Information Services
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

MARKDOWN
Price trending down — defensive positioning
0.570
Good returns relative to risk taken
0.0488
Modest edge detected — smaller position warranted
0.349
Drawdown risk outweighs the returns — higher risk profile
Annual Return
18.7%
Historical annualised return based on price data
-53.6%
Largest peak-to-trough decline — the worst it has been
BEAR
Statistical model detects bearish conditions
Days in State
1
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

0.96
Less volatile than the market — more defensive
52W High
$55.00
22% below the year high
52W Low
$26.85
60% above the year low
Avg Volume
567,422
Average daily shares traded — higher means easier to buy and sell
4.1
Days it would take all short sellers to cover — higher means more crowded
Short % Float
7.2%
Moderate short interest
N/A
Annual dividend as a percentage of the share price
$0.44
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

16.09
Heavy leverage — higher financial risk if revenues decline
1.50
Adequate but worth monitoring
Quick Ratio
1.04
Like current ratio but excludes inventory — stricter test
Gross Margin
43.9%
Revenue left after cost of goods — higher means pricing power
Operating Margin
5.4%
Profit from core operations before interest and tax
$113M
Positive — the business generates more cash than it spends
Revenue (TTM)
$1.2B
Total revenue over the last 12 months
Net Income
$20M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
7
Target High
$70.00
Target Median
$60.00
Target Low
$55.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.